GKOS — Glaukos Corporation

Glaukos Corporation (GKOS) Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Sales: Q3 2025 consolidated net sales reached $133.5 million, a 38% increase year-over-year (37% on a constant currency basis).
• U.S. Glaucoma Franchise: Achieved record sales of $80.8 million, up 57% year-over-year, driven by iDose TR sales of approximately $40 million.
• International Glaucoma Franchise: Reported net sales of $29.4 million, reflecting 20% growth (17% constant currency).
• Corneal Health Franchise: Generated $23.3 million in sales, a 13% increase, with Photrexa contributing $20.3 million.
• Gross Margin: Continued improvement noted, with a strong balance sheet showing $278 million in cash and no debt.
• Revised Guidance: Full-year 2025 net sales guidance raised to $490 million - $495 million from the previous $480 million - $486 million.

2. Strategic Updates and Business Highlights

• Epioxa Approval: FDA approved Epioxa, a new treatment for keratoconus, marking a significant milestone as the first incision-free topical therapy for the condition.
• Market Development Initiatives: Plans to enhance patient awareness and access through education campaigns, partnerships with optometrists, and a new handheld screening device.
• iDose TR Adoption: Continued momentum in adoption, with ongoing clinical studies to validate its use in combination with cataract surgery and other MIGS devices.
• New Facility: Groundbreaking on a 200,000 square foot R&D and manufacturing facility in Huntsville, Alabama, to support future growth.

3. Forward Guidance and Outlook

• 2026 Preliminary Guidance: Introduced a preliminary revenue range of $600 million - $620 million, factoring in the continued rollout of iDose TR and the launch of Epioxa.
• Long-term Growth Potential: Anticipated growth in the glaucoma market, with a focus on expanding treatment access for keratoconus patients.

4. Bad News, Challenges, or Points of Concern

• Transition from Photrexa: Expected decline in Corneal Health sales as the company transitions from Photrexa to Epioxa, with a noted material year-over-year decline anticipated in Q4 2025.
• Payer Coverage and Reimbursement: Concerns regarding the education and acceptance of Epioxa by payers, especially given the high price point of $78,500.
• Market Access Headwinds: Challenges in establishing coverage and reimbursement for iDose TR, particularly with ongoing discussions with MACs and the upcoming CAC meeting.
• Patient Access Issues: Only 10,000 patients currently treated annually with Photrexa, with many patients still undiagnosed or untreated, indicating a significant opportunity but also a challenge in patient outreach.

5. Notable Q&A Insights

• iDose TR Utilization: The ramp-up in iDose sales is expected to continue, with a mix of standalone and combination procedures, though specific tracking of combinations is challenging.
• Epioxa Market Strategy: The company plans to invest heavily in awareness and education to improve patient access, especially targeting younger patients at risk of keratoconus.
• Clinical Study Timelines: Ongoing studies for iDose in combination with cataract surgery are expected to yield results by late 2026 or early 2027.
• Payer Engagement: The company is actively engaging with payers to educate them on the benefits of Epioxa and establish coverage, with optimism about the potential for favorable outcomes.

Overall, Glaukos reported a strong quarter with significant growth in net sales and strategic advancements, particularly with the launch of Epioxa. However, challenges related to market access, transitioning from existing therapies, and establishing payer coverage remain critical areas of focus moving forward.